Combination therapy in asthma -fixed or variable dosing in different patients?

References

• Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993;147:697–704
   Google Scholar
• Boulet LP, Cartier A, Milot J, Cote J, Malo JL, Laviolette M. Tolerance to the protective effects of salmeterol on methacholine-induced brochoconstriction: influence of inhaled corticosteroids. Eur Respir J 1998;11:1091–7
   PubMed Web of Science ®Google Scholar
• Haahtela T. Airway remodelling takes place in asthma – what are the clinical implications? Clin Exp Allergy 1997;27:351–3
   PubMed Web of Science ®Google Scholar
• Haahtela T, Jarvinen M, Kava T, et al. Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388–92
   PubMed Web of Science ®Google Scholar
• Selroos O, Pietinalho A, Löfroos A-B, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995;108:1228–34
   Google Scholar
• Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003;22:787–94
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). NHLBI/WHO workshop report: global strategy for asthma management and prevention (revised 2002). NIH Publication No. 02–3659. Available from www.ginasthma.com [Accessed 5 May 2004]
   Google Scholar
• British Thoracic Society. British guidelines on the management of asthma. Thorax 2003;58(Suppl 1):i1–94
   PubMedGoogle Scholar
• Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Relief in Europe (AIRE) study. Eur Respir J 2000;16:802–7
   PubMed Web of Science ®Google Scholar
• Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219–24
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405–11
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10:2484–9
   Google Scholar
• Seberová E, Andersson A. Oxis (formoterol given by Turbuhaler^®) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000;94:607–11
   Google Scholar
• van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996;9:1684–8
   Google Scholar
• Rabe KF, Jörres R, Nowak D, Behr N, Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24-hours in bronchial asthma. Am Rev Respir Dis 1993;147:1436–41
   PubMed Web of Science ®Google Scholar
• van der Molen T, Postma DS, Turner MO, et al. Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997;52:535–9
   PubMed Web of Science ®Google Scholar
• Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis 1990;142:571–5
   Google Scholar
• Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci 1993;52:2145–60
   PubMed Web of Science ®Google Scholar
• Rong Y, Arbabian M, Thiriot DS, Seibold A, Clark RB, Ruoho AE. Probing the salmeterol binding site on the β2-adrenergic receptor using a novel photoaffinity ligand [(125)I]-iodoazidosalmeterol. Biochemistry 1999;38:11278–86
   PubMed Web of Science ®Google Scholar
• Lindén A, Bergendal A, Ullman A, Skoogh BE, Löfdahl CG. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993;48:547–53
   Google Scholar
• Palmqvist M, Ibsen T, Mellén A, Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999;160:244–9
   PubMed Web of Science ®Google Scholar
• Malolepszy J, Böszörményi Nagy G, Selroos O, Larsso P, Brander R. Safety of formoterol Turbuhaler® at cumulative dose of 90 mg in patients with acute bronchial obstruction. Eur Respir J 2001;18:928–34
   PubMed Web of Science ®Google Scholar
• Beach JR, Bromly CL, Avery AJ, Reid RW, Walters EH, Hendrick DJ. Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction. Pulm Pharmacol 1996;9:245–9
   PubMedGoogle Scholar
• Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999;13:988–92
   Google Scholar
• Tattersfield AE, Löfdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001;357:257–61
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Pedersen S, Busse WW, et al, on behalf of the START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003;361:1071–6
   Google Scholar
• Sears MR, Pauwels RA, Campbell M, et al. Safety of formoterol turbuhaler used as reliever in asthma: relationship with age and baseline treatment including regular long-acting β2-agonists (the RELIEF study). Eur Respir J 2002;20\(Suppl 38):44s [Abstract P393]
   Google Scholar
• Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998;114:411–5
   PubMed Web of Science ®Google Scholar
• Mettauer B, Rouleau JL, Burgess JH. Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure. Am Heart J 1985;109:840–7
   Google Scholar
• Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lötvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol 2000;56:363–70
   Google Scholar
• Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol; a dose–response comparison in healthy subjects. Thorax 2000;55:650–6
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Medwatch. 2003 Safety Alert – Serevent (salmeterol xinafoate). Available from www.fda.gov/medwatch/SAFETY/2003/serevent.htm [Accessed on 5 May 2004]
   Google Scholar
• Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. J Am Med Assoc 2001;285:2583–93
   PubMed Web of Science ®Google Scholar
• Boulet L-P, Turcotte H, Laviolette M, et al. Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Am J Respir Crit Care Med 2000;162:1308–13
   Google Scholar
• Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997;99:655–9
   Google Scholar
• Giannini D, Di Franco A, Bacci E, et al. Tolerance to the protective effect of salmeterol on allergen challenge can be partially restored by the withdrawal of salmeterol regular treatment. Chest 2001;119:1671–5
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392–7
   Google Scholar
• Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481–8
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. J Am Med Assoc 2001;285:2594–603
   Web of Science ®Google Scholar
• Kips JC, O’Connor JB, Inman MD, Svensson K, Pauwels RA, O’Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000;161:996–1001
   PubMed Web of Science ®Google Scholar
• McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924–30
   PubMed Web of Science ®Google Scholar
• Howarth P. Effects of β2-agonists on airway inflammation: β2-agonists in asthma treatment. In: Pauwels R, O’Byrne PM, editors. Lung biology in health and disease. New York: Marcel Dekker; 1997:67–86
   Google Scholar
• Chung KF. The complementary role of glucocorticoids and long-acting β-adrenergic agonists. Allergy 1998;53(42 Suppl):7–13
   PubMedGoogle Scholar
• Mak JC, Nishikawa M, Barnes PJ. Glucocorticoids increase β2-adrenergic receptor transcription in human lung. Am J Physiol 1995;268(1 Pt 1):L41–6
   Google Scholar
• Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005–10
   PubMed Web of Science ®Google Scholar
• Korn SH, Jerre A, Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur Respir J 2001;17: 1070–7
   Google Scholar
• Pang L, Knox AJ. Synergistic inhibition by β2-agonists and corticosteroids on tumor necrosis factor-α-induced interleukin-8 release from cultured human airway smooth muscle cells. Am J Respir Cell Mol Biol 2000;23:79–85
   PubMed Web of Science ®Google Scholar
• Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50mg and fluticasone propionate 250mg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000;161:527–34
   PubMed Web of Science ®Google Scholar
• Bateman ED, Britton M, Carrillo J, Almeida J, Wixon C. Salmeterol/fluticasone combination inhaler. A new, effective and well-tolerated treatment for asthma. Clin Drug Invest 1998;16:193–201
   Google Scholar
• Aubier M, Pieters WR, Schlösser NJJ, Steinmetz K-O. Salmeterol/fluticasone propionate (50/500 mg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999;93: 876–84
   Google Scholar
• Chapman KR, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M. Salmeterol and fluticasone propionate (50/250 mg) administered via a combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999;6:45–51
   PubMedGoogle Scholar
• Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001;18:262–8
   Google Scholar
• Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003;123:1480–7
   PubMed Web of Science ®Google Scholar
• Jenkins C, Woolcock AJ, Saarelainen P, Lundback B, James MH. Salmeterol/fluticasone propionate combination therapy 50/250 mg twice daily is more effective than budesonide 800 mg twice daily in treating moderate to severe asthma. Respir Med 2000;94: 715–23
   Google Scholar
• Lundback B, Jenkins C, Price MJ, Thwaites RM. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250mg twice daily and budesonide 800mg twice daily in the treatment of adults and adolescents with asthma. Respir Med 2000;94:724–32
   PubMed Web of Science ®Google Scholar
• Price MJ, Sondhi S, Yan S, Nyth A, House K. Salmeterol/fluticasone propionate combination inhaler is more cost-effective than fluticasone propionate in patients with asthma. Eur Respir J 1999;14(Suppl 30):370s
   Google Scholar
• Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lötvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001;14:29–34
   PubMed Web of Science ®Google Scholar
• Eisner MD, Lieu TA, Chi F, et al. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001;17:233–40
   PubMed Web of Science ®Google Scholar
• van der Palen J, Klein JJ, van Herwaarden CLA, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999;14:1034–7
   PubMed Web of Science ®Google Scholar
• Chapman KR, Walker L, Cluley S, Fabbri L. Improving patient compliance with asthma therapy. Respir Med 2000;94:2–9
   PubMed Web of Science ®Google Scholar
• Rosenhall L, Elvstrand A, Tilling B, et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler®) for the treatment of asthma. Respir Med 2003;97:702–8
   PubMed Web of Science ®Google Scholar
• Ringdal N, Chuchalin A, Chovan L, Tudoric N, Maggi E, Whitehead PJ. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide™ (50/250 mg bd) Diskus™ vs. formoterol (12 mg bd) and budesonide (800 mg bd) given concurrently (both via Turbuhaler^™) in patients with moderate-to-severe asthma. Respir Med 2002;96:851–61
   Google Scholar
• Barnes PJ, Pederson S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157(3 Pt 2 Suppl):S1–53
   Google Scholar
• Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998;101:457–63
   PubMed Web of Science ®Google Scholar
• Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose–response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Br Med J 2001;323:253–6
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med 1999;159:941–55
   PubMed Web of Science ®Google Scholar
• Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000;117:440–6
   Google Scholar
• Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest 2000;117:542–50
   Google Scholar
• Cochrane GM. Compliance and outcomes in patients with asthma. Drugs 1996;52(Suppl 6):12–9
   PubMed Web of Science ®Google Scholar
• Buston KM, Wood SF. Non-compliance amongst adolescents with asthma: listening to what they tell us about self-management. Fam Pract 2000;17:134–8
   PubMed Web of Science ®Google Scholar
• Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501–6
   PubMed Web of Science ®Google Scholar
• Kips JC, Pauwels RA. Airway wall remodelling: does it occur and what does it mean? Clin Exp Allergy 1999;29:1457–66
   PubMed Web of Science ®Google Scholar
• Olivieri D, Chetta A, Del Donno M, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997;155:1864–71
   PubMed Web of Science ®Google Scholar
• Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. J Am Med Assoc 1992;268:3462–4
   PubMed Web of Science ®Google Scholar
• Donaghue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. J Am Med Assoc 1997;277:887–91
   Web of Science ®Google Scholar
• Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881–4
   Google Scholar
• Pechère J-C. Parameters important in short antibiotic courses. J Int Med Res 2000;28\(Suppl 1):3–12A
   Google Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002;19:182–91
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Sears MR, Boulet LP, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 2003;10:427–34
   PubMedGoogle Scholar
• Aalbers R, Backer V, Kava TTK, Omenaas ER, Sandström T, Jorup C, Welte T. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/ fluticasone. Curr Med Res Opin 2004;20:225–40
   Google Scholar
• Ind P, Haughney J, Price D, Rosen J-P, Kennelly J. Managed adjustable dosing of budesonide/formoterol combination provides equivalent asthma control to fixed dosing at a lower overall dose. Eur Respir J 2002;20\(Suppl 38):396s [Abstract P2450]
   Google Scholar
• Ind P, Haughney J, Price D, Rosen J-P, Kennelly J. Four-month adjustable or fixed maintenance treatment with budesonide/formoterol in a single inhaler reduces symptom severity. Eur Respir J 2002;20\(Suppl 38):41s [Abstract P378]
   Google Scholar
• Ställberg B, Olsson P, Jorgensen LA, Lindarck N, Ekström T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003;57:656–61
   Google Scholar
• Price D, Haughney J, Hutchinson J, Lloyd A, Plumb J. Budesonide/formoterol with an adjustable maintenance plan costs less and is as effective as fixed dosing. Eur Respir J 2002;20\(Suppl 38):397s [Abstract P2452]
   Google Scholar
• van der Woude HJ, Boorsma M, Bergqvist PBF, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004;17:89–95
   PubMed Web of Science ®Google Scholar
• van der Woude HJ, Boorsma M, Bergqvist PBF, Winter TH, Aalbers R. More rapid relief of methacholine-induced bronchoconstriction with budesonide/formoterol than with salmeterol/fluticasone. Eur Respir J 2001;18\(Suppl 33):53s [Abstract 451749]
   Google Scholar